Form 4: Evolent Health Director Reports Stock Transaction

Evolent Health Director Jill D. Smith reported a transaction involving Class A Common Stock, acquiring 41,096 shares under an incentive plan.

Summary

• Jill D. Smith, a Director at Evolent Health, Inc., reported a transaction on June 4, 2026.
• The transaction involved the acquisition of 41,096 shares of Class A Common Stock.
• These securities were granted as restricted stock units (RSUs) under the company's 2015 Omnibus Incentive Compensation Plan.
• The acquisition was valued at $0, indicating it was part of a stock grant.
• Following this transaction, Ms. Smith beneficially owns 64,233 shares of Class A Common Stock.
• The RSUs vest on June 4, 2027, or the date of the company's 2027 annual meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard stock grant to a director as part of an existing incentive plan, with no immediate financial impact or significant strategic shift indicated.

Positives

• Director Jill D. Smith received a significant grant of 41,096 Class A Common Stock units, indicating continued investment in the company's equity by a key insider.
• The stock grant is part of a long-term incentive plan, aligning the director's interests with those of shareholders for the vesting period extending to 2027.

Risks

• The vesting of the restricted stock units is contingent upon the reporting person's continued service, meaning any departure before June 4, 2027, or the 2027 annual meeting would result in forfeiture of these shares.

Future Outlook

The restricted stock units granted to Ms. Smith are set to vest on June 4, 2027, or the date of the company's 2027 annual meeting, provided she remains in service.

Industry Context

StockSavvy.ai notes that insider stock grants, as reported in this Form 4 filing by Evolent Health, are a common practice in the health technology and managed care sectors to attract and retain key leadership talent by aligning their financial interests with long-term company performance.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with long-term company performance, potentially benefiting shareholders if the company's value increases by the vesting date.

Next Steps

• Ms. Smith's restricted stock units will vest on June 4, 2027, or the date of the company's 2027 annual meeting, contingent on her continued service.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, Class A Common Stock, Director, Beneficial Ownership, Incentive Compensation Plan